KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Debt to Equity (2017 - 2023)

Bionano Genomics (BNGO) has disclosed Debt to Equity for 7 consecutive years, with $0.08 as the latest value for Q3 2023.

  • Quarterly Debt to Equity rose 154.5% to $0.08 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $0.08 through Sep 2023, up 154.5% year-over-year, with the annual reading at $0.04 for FY2022, N/A changed from the prior year.
  • Debt to Equity hit $0.08 in Q3 2023 for Bionano Genomics, up from $0.05 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $5.56 in Q4 2019 to a low of -$14.44 in Q2 2019.
  • Historically, Debt to Equity has averaged -$0.53 across 5 years, with a median of $0.04 in 2021.
  • Biggest YoY gain for Debt to Equity was 524.12% in 2019; the steepest drop was 552.21% in 2019.
  • Year by year, Debt to Equity stood at $5.56 in 2019, then plummeted by 91.63% to $0.47 in 2020, then crashed by 91.19% to $0.04 in 2021, then decreased by 8.21% to $0.04 in 2022, then surged by 123.39% to $0.08 in 2023.
  • Business Quant data shows Debt to Equity for BNGO at $0.08 in Q3 2023, $0.05 in Q2 2023, and $0.04 in Q1 2023.